Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
Journal of Thoracic Oncology2025cited by 14position: middledoi
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.
Journal of Clinical Oncology2024cited by 16position: middledoi
Using Item‐Response Theory to Improve Interpretation of the Trans Woman Voice Questionnaire
The Laryngoscope2022cited by 14position: middledoi